$48.14
3.427.65%
At Close: -
$48.32
0.180.37%
After Hours: Jul 26, 6:45 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Avidity Biosciences (NASDAQ:RNA) Stock, Analyst Ratings, Price Targets, Forecasts
Avidity Biosciences Inc has a consensus price target of $46.2 based on the ratings of 10 analysts. The high is $71 issued by Raymond James on December 15, 2022. The low is $20 issued by Evercore ISI Group on March 31, 2023. The 3 most-recent analyst ratings were released by B of A Securities, Needham, and Chardan Capital on June 13, 2024, June 12, 2024, and June 12, 2024, respectively. With an average price target of $45.33 between B of A Securities, Needham, and Chardan Capital, there's an implied -6.18% downside for Avidity Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
Needham
Chardan Capital
Evercore ISI Group
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Avidity Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/13/2024 | Buy Now | -6.87% | B of A Securities | Geoff Meacham | $40 → $45 | Maintains | Buy | Get Alert |
| 06/12/2024 | Buy Now | -4.8% | Needham | Joseph Stringer | $35 → $46 | Maintains | Buy | Get Alert |
| 06/12/2024 | Buy Now | -6.87% | Chardan Capital | Keay Nakae | $33 → $45 | Maintains | Buy | Get Alert |
| 06/12/2024 | Buy Now | -6.87% | Evercore ISI Group | Josh Schimmer | $40 → $45 | Maintains | Outperform | Get Alert |
| 06/10/2024 | Buy Now | -27.57% | Needham | Joseph Stringer | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | -27.57% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | -31.71% | Chardan Capital | Keay Nakae | $33 → $33 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | -17.22% | B of A Securities | Geoff Meacham | → $40 | Initiates | → Buy | Get Alert |
| 04/11/2024 | Buy Now | -27.57% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | Buy Now | 24.17% | Cantor Fitzgerald | Eric Schmidt | → $60 | Initiates | → Overweight | Get Alert |
| 03/05/2024 | Buy Now | -31.71% | Chardan Capital | Keay Nakae | $23 → $33 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | -27.57% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | -27.57% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | -52.4% | Chardan Capital | Keay Nakae | → $23 | Reiterates | Buy → Buy | Get Alert |
| 01/03/2024 | Buy Now | 3.48% | Wells Fargo | Yanan Zhu | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/29/2023 | Buy Now | -27.57% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | -37.91% | Credit Suisse | Judah Frommer | → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2023 | Buy Now | -52.4% | Chardan Capital | Keay Nakae | $27 → $23 | Maintains | Buy | Get Alert |
| 08/09/2023 | Buy Now | -27.57% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2023 | Buy Now | -58.61% | Evercore ISI Group | Josh Schimmer | → $20 | Upgrade | In-Line → Outperform | Get Alert |
| 05/17/2023 | Buy Now | -27.57% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 3.48% | Wells Fargo | Yanan Zhu | $55 → $50 | Maintains | Overweight | Get Alert |
| 05/10/2023 | Buy Now | -37.91% | Credit Suisse | Judah Frommer | → $30 | Reiterates | → Outperform | Get Alert |
| 04/28/2023 | Buy Now | -27.57% | Needham | Joseph Stringer | → $35 | Reiterates | → Buy | Get Alert |
| 03/31/2023 | Buy Now | -37.91% | Credit Suisse | Judah Frommer | $35 → $30 | Maintains | Outperform | Get Alert |
| 03/31/2023 | Buy Now | -58.61% | Evercore ISI Group | Joshua Schimmer | → $20 | Downgrade | Outperform → In-Line | Get Alert |
| 03/31/2023 | Buy Now | -44.12% | Chardan Capital | Keay Nakae | → $27 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | -27.57% | Credit Suisse | Judah Frommer | → $35 | Reiterates | → Outperform | Get Alert |
| 03/01/2023 | Buy Now | -44.12% | Chardan Capital | Keay Nakae | → $27 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | -27.57% | Needham | Joseph Stringer | → $35 | Reiterates | → Buy | Get Alert |
| 01/04/2023 | Buy Now | 13.82% | Wells Fargo | Yanan Zhu | $60 → $55 | Maintains | Overweight | Get Alert |
| 12/15/2022 | Buy Now | -27.57% | Credit Suisse | Judah Frommer | $33 → $35 | Maintains | Outperform | Get Alert |
| 12/15/2022 | Buy Now | 46.94% | Raymond James | Steven Seedhouse | $30 → $71 | Maintains | Strong Buy | Get Alert |
| 12/14/2022 | Buy Now | 46.94% | Raymond James | Steven Seedhouse | $30 → $71 | Maintains | Strong Buy | Get Alert |
| 11/09/2022 | Buy Now | -31.71% | Credit Suisse | Judah Frommer | $32 → $33 | Maintains | Outperform | Get Alert |
| 11/09/2022 | Buy Now | -37.91% | Raymond James | Steven Seedhouse | $29 → $30 | Maintains | Strong Buy | Get Alert |
| 09/27/2022 | Buy Now | -27.57% | Needham | Joseph Stringer | $50 → $35 | Maintains | Buy | Get Alert |
| 09/27/2022 | Buy Now | -44.12% | Chardan Capital | Keay Nakae | $29 → $27 | Maintains | Buy | Get Alert |
| 07/20/2022 | Buy Now | -39.98% | Chardan Capital | Keay Nakae | → $29 | Initiates | → Buy | Get Alert |
| 07/12/2022 | Buy Now | -39.98% | Raymond James | Steven Seedhouse | → $29 | Initiates | → Strong Buy | Get Alert |
| 05/11/2022 | Buy Now | -33.77% | Credit Suisse | Judah Frommer | $36 → $32 | Maintains | Outperform | Get Alert |
| 05/11/2022 | Buy Now | 3.48% | SVB Leerink | Joseph Schwartz | $53 → $50 | Maintains | Outperform | Get Alert |
| 12/10/2021 | Buy Now | 9.69% | SVB Leerink | Joseph Schwartz | — | Maintains | Outperform | Get Alert |
| 09/07/2021 | Buy Now | 3.48% | Evercore ISI Group | Josh Schimmer | — | Initiates | → Outperform | Get Alert |
| 08/10/2021 | Buy Now | -25.5% | Credit Suisse | Judah Frommer | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Avidity Biosciences (RNA) stock?
The latest price target for Avidity Biosciences (NASDAQ:RNA) was reported by B of A Securities on June 13, 2024. The analyst firm set a price target for $45.00 expecting RNA to fall to within 12 months (a possible -6.87% downside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Avidity Biosciences (RNA)?
The latest analyst rating for Avidity Biosciences (NASDAQ:RNA) was provided by B of A Securities, and Avidity Biosciences maintained their buy rating.
When was the last upgrade for Avidity Biosciences (RNA)?
The last upgrade for Avidity Biosciences Inc happened on May 22, 2023 when Evercore ISI Group raised their price target to $20. Evercore ISI Group previously had an in-line for Avidity Biosciences Inc.
When was the last downgrade for Avidity Biosciences (RNA)?
The last downgrade for Avidity Biosciences Inc happened on March 31, 2023 when Evercore ISI Group changed their price target from N/A to $20 for Avidity Biosciences Inc.
When is the next analyst rating going to be posted or updated for Avidity Biosciences (RNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avidity Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avidity Biosciences was filed on June 13, 2024 so you should expect the next rating to be made available sometime around June 13, 2025.
Is the Analyst Rating Avidity Biosciences (RNA) correct?
While ratings are subjective and will change, the latest Avidity Biosciences (RNA) rating was a maintained with a price target of $40.00 to $45.00. The current price Avidity Biosciences (RNA) is trading at is $48.32, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.